Edition 57: The 1% Problem Every Indian Pharma CEO Is Ignoring
India’s pharma market grew 8.1% last year. Only 1.5% came from real demand. Why the other 6.6% is a slow-moving crisis, and how...
Read perspective →
Edition 50: India's GLP-1 Inflection Point
Semaglutide went generic and prices collapsed to ~Rs1,290/month. India’s GLP-1 market moved from premium to mass-market in one ...
Read perspective →
Edition 33: Generic Medicines at Scale: Jan Aushadhi's 16,900+ stores
Medicines are ~two-thirds of Indian families’ health spend. Jan Aushadhi’s 16,900+ stores sell generics 50-90% cheaper, and the...
Read perspective →
Edition 24: India's Pharma Paradox: Big Market, Bigger Gaps
India supplies 20% of global generics and 60% of vaccines, yet imports 65-70% of APIs from China, spends only 6-8% on R&D, ...
Read perspective →